United States · 
What does Frazier Life Sciences invest in?
Frazier Life Sciences invests most often at Series A and Series B (75% of the rounds on record), in sectors such as Biotech, Therapeutics and Oncology.
Frazier Life Sciences highlights
- 01
6 cheques in the last 12 months
- 02
Mostly Series A and Series B: 75% of its rounds
- 03
Led 6 rounds
What they do
Frazier Life Sciences is a longstanding biotech investment firm with venture and public strategies partnering with and building companies developing novel therapeutics.From their own website
- Type
- VC firm
- Cheque size
- Not stated
- Sectors
- BiotechTherapeuticsOncology
- Based in
- Seattle, United States
- Cold pitches
- Not stated
The record
Every round we can evidence, newest first9 appearances
- 2026
5 rounds
- Oct
- Jul
- Jun
- Jun
- Apr
- 2025
3 rounds
- Nov
- Mar
- Jan
- 2024
1 round
- Nov
An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.
The team
Named by the firm itself, on a filing, its Form ADV or its company registration11 named
ADAlan D. FrazierMember of the Issuer's affiliated advisor, Frazier Management, L.L.C.iFiling they signed
A(Albert (nmn) ChaManaging Member of the GP of the GPiFiling they signed
DJDaniel J. EstesMember of the General Partner of the General PartneriFiling they signed
JBJames BrushGeneral Partner & Portfolio ManageriForm ADV
JNJames Newman TopperMember of the General Partner of the General PartneriFiling they signed
JBJamie BrushManaging Member of the GP of the GPiFiling they signed
JTJamie TopperManaging Member of the GP of the GPiFiling they signed
NDNader D. NainiMember of the Issuer's affiliated advisor, Frazier Management, L.L.C.iFiling they signed
NDNathan D. EveryMember of the Issuer's affiliated advisor, Frazier Management, L.L.C.iFiling they signed
PJPatrick James HeronMember of the General Partner of the General PartneriFiling they signed
SRSteve Ray BaileyChief Financial Officer & Chief Compliance OfficeriForm ADV
We also hold 29 people at this firm from the lists this database was built from: a weaker source than the filings, since a list does not say when a title ended. Login to see them.
What the register says
From the firm's own filings with the SEC, which it must file accurately by law
$7.0Bassets it managesOct 2026
Registeredinvestment adviserfull reporting to the SEC
- Legal name
- Frazier LIFE Sciences Management, LP
- SEC number
- CRD 317522
Funds on its Form ADV
8 private funds, $2.7B in gross assets · filed Mar 2024
Private equity 3Venture 3Hedge 2
- Frazier Life Sciences Public Fund, L.P.Hedge119 investors$900M
- Frazier Life Sciences X, L.P.Private equity72 investors$567M
- Frazier Life Sciences IX, L.P.Venture54 investors$404M
- Frazier Life Sciences XI, L.P.Venture99 investors$316M
- Frazier Life Sciences Public Overage Fund, L.P.Hedge61 investors$281M
- Frazier Life Sciences VIII, L.P.Venture45 investors$161M
- Frazier Healthcare VII, L.P.Private equity39 investors$57M
- Frazier Healthcare VII-A, L.P.Private equity5 investors$16M
What they claim to have backed
From their own portfolio page (on their website)
28 of 48 we have independently watched raise
35pharmaAcerta-pharmaAlcrestaAlentisAlestatherapeuticsAnaptysbioArcutisAspenneuroscienceBridgebioCidaraDecipheraDiscmedicineErascaGondolabioGritstonebioHillstarbioHummingbirdbioscienceImmutrinInipharmNewamsterdampharmaPassagebioPhathompharmaRaptRigelRqbiotechnologyScoutbioSidewinderbioStar-therapeuticsAdverumAirnexisAngitiabioArchitecttherapeuticsAttoviaBraveheartCollegiumpharmaCompletepharmacysolutionsEyconisKalvistaKnipperKrystalbioMbxbioMirumpharmaOrapharmaParabilismedRadioneticsScilexholdingSudobioZemdri
Weaker than a round we watched, stronger than a list somebody sold us. A firm is far less willing to put a company on its own site that it never funded.